Compare GSK plc (GSK) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Roundhill Magnificent Seven ETF — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Roundhill Magnificent Seven ETF trades at $73.75 (market cap $5.78B). The key difference: GSK plc is far larger — about 15.9× Roundhill Magnificent Seven ETF's market cap, and GSK plc pays a 3.9% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| GSK | MAGS | |
|---|---|---|
Market Cap | $91.88B | $5.78B |
Volume | 7,730,529 | 4,410,665 |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $73.90 |
52-Week Low | $43.24 | $55.39 |
Typical Hold Time | 93 Days | 36 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
MAGS trades at $73.66, showing minimal daily movement with a slight 0.04% decline. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF provides equal-weighted exposure to the Magnificent Seven mega-cap tech stocks, though recent performance has trailed broader market indexes with modest 2% year-to-date gains.
The outlook remains cautiously optimistic given the ETF's concentrated tech exposure and AI growth themes. Key risks include market concentration, valuation concerns, and potential regulatory scrutiny. Wall Street sentiment appears mixed as investors weigh long-term AI potential against near-term performance challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
